news L1 compound identified as potential treatment for Alzheimer’s disease 11 May 2020 | By Victoria Rees (Drug Target Review) A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
news Multivalent carbohydrate-binding modules show efficacy against COVID-19 8 May 2020 | By Victoria Rees (Drug Target Review) Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
news Researchers analyse SARS-CoV-2 genome, identifying 198 mutations 7 May 2020 | By Victoria Rees (Drug Target Review) After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
article Begin with the end in mind: designing synthetic antibiotics with a universal mechanism of action 6 May 2020 | By Victoria Rees (Drug Target Review) James Graham from Recce Pharmaceuticals discusses how a new class of synthetic antibiotics could be the key to preventing the spread of antibiotic resistance.
news Novel target for Sjögren’s Syndrome identified by researchers 6 May 2020 | By Victoria Rees (Drug Target Review) A molecule called microRNA-744, which influences inflammation, has been revealed by researchers as a new drug target for Sjögren's Syndrome.
news Study finds activation sequence of COVID-19 S protein is cleaved by furin protease 6 May 2020 | By Victoria Rees (Drug Target Review) Researchers have shown that the activation sequence the SARS-CoV-2 S protein is cleaved by the cellular enzyme furin which is also required for the infection of lung cells.
news Researchers identify monoclonal antibody to neutralise COVID-19 5 May 2020 | By Victoria Rees (Drug Target Review) An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
news Cytokine storms and T-cell counts may offer clues on COVID-19 treatment 4 May 2020 | By Victoria Rees (Drug Target Review) According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
article Intravenous immunoglobulins, hyperimmunes and pandemic viruses 4 May 2020 | By Hannah Balfour (Drug Target Review) David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
news Researchers reveal cryo-EM structure of remdesivir bound to SARS-CoV-2 4 May 2020 | By Victoria Rees (Drug Target Review) A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
news Researchers reveal structure of mega-enzymes from bacteria and fungi 1 May 2020 | By Victoria Rees (Drug Target Review) Researchers have uncovered the structure of nonribosomal peptide synthetases (NRPSs), an important ingredient in drug production.
news Researchers suggest COVID-19 therapeutics needed to target blood vessel leakage 1 May 2020 | By Victoria Rees (Drug Target Review) According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
news Collaboration to identify novel COVID-19 drug targets announced 30 April 2020 | By Hannah Balfour (Drug Target Review) Bringing together protein science, drug discovery experience and innovative technology, a new collaboration aims to identify novel drug targets for COVID-19.
news Silicates from soil aid in triggering blood clotting, reveal researchers 30 April 2020 | By Victoria Rees (Drug Target Review) A new study has revealed that the presence of soil in wounds helps to activate a blood protein known as coagulation Factor XII, leading to clotting.
news Antibodies developed from llama show promise in fighting COVID-19 30 April 2020 | By Victoria Rees (Drug Target Review) Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
